Compare HGV & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HGV | TVTX |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | N/A |
| Metric | HGV | TVTX |
|---|---|---|
| Price | $45.27 | $33.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $49.75 | $37.21 |
| AVG Volume (30 Days) | 795.1K | ★ 1.5M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $4,470,000,000.00 | $435,826,000.00 |
| Revenue This Year | $14.74 | $120.36 |
| Revenue Next Year | $9.35 | $37.33 |
| P/E Ratio | $80.26 | ★ N/A |
| Revenue Growth | 5.47 | ★ 114.22 |
| 52 Week Low | $30.59 | $12.91 |
| 52 Week High | $52.08 | $37.50 |
| Indicator | HGV | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 47.81 |
| Support Level | $42.70 | $33.84 |
| Resistance Level | $44.49 | $36.24 |
| Average True Range (ATR) | 1.24 | 1.61 |
| MACD | 0.41 | -0.30 |
| Stochastic Oscillator | 77.60 | 7.90 |
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.